Adagio Medical is developing catheter-based therapies that utilize advanced ablation techniques to treat atrial fibrillation and other cardiovascular conditions. The company aims to improve patient outcomes by providing targeted interventions that reduce the risk of stroke and enhance heart rhythm stability.

Beta Bionics develops the iLet Bionic Pancreas, an insulin delivery system that autonomously calculates and administers insulin doses based on real-time data from continuous glucose monitors. This technology eliminates the need for manual carb counting and insulin dose adjustments, providing a streamlined solution for diabetes management.

Capstan Therapeutics develops targeted lipid nanoparticles (tLNPs) that deliver mRNA and gene editing tools to specific cell types in vivo, enabling precise reprogramming of cells for therapeutic purposes. This technology addresses the need for effective treatments across various diseases, including oncology and genetic disorders, by facilitating safe and repeatable dosing with tailored payloads.

Crossover provides a proprietary Care Platform that unifies primary care, physical medicine, mental health, health coaching, and occupational medicine into a single, 50‑state virtual network.

Earli develops programmable genetic constructs that activate exclusively in cancer cells, prompting them to self-identify and undergo apoptosis. This technology addresses the challenge of early cancer detection and targeted therapy by enabling precise identification of malignant cells without affecting healthy tissue.

Freenome provides a blood‑based early cancer detection platform that uses multiomics profiling—integrating genomics, epigenomics, proteomics, and metabolomics—with AI‑driven analysis to identify cancer at its most treatable stages. The minimally invasive test is designed for routine screening across multiple cancer types and is validated through ongoing clinical programs for use by healthcare providers.

The startup provides genomic medicine delivery by connecting individuals and healthcare providers with genetic experts for personalized genetic assessments and clinical action plans. This approach enables patients to make informed treatment decisions while facilitating faster disease diagnosis for medical practitioners at reduced costs.

Kindbody operates a network of modern, tech-enabled fertility clinics that provide services such as in vitro fertilization (IVF), egg freezing, and comprehensive reproductive health care. The company addresses the lack of accessible and transparent fertility care by offering employer-sponsored family-building benefits and financing options, ensuring patients receive personalized support throughout their family-building journey.

Neuron23 develops precision medicines targeting genetically defined neurological diseases, specifically Parkinson's and Alzheimer's, by utilizing advanced data science and human genetics to identify novel molecular targets. Their approach aims to create effective treatments that address the unmet medical needs of patients suffering from these debilitating conditions.

Omada Health provides a virtual, multi‑condition care program that pairs members with certified health coaches, educators, and therapists, delivering personalized health plans, weekly lessons, and peer‑support groups. Connected devices automatically sync biometric data for real‑time monitoring, and the platform integrates with electronic health records to give clinicians actionable insights. The service is offered through employers and health plans at no cost to eligible individuals, aiming to improve chronic disease management and overall health outcomes.

OnKure Therapeutics discovers and develops tumor‑agnostic small‑molecule therapies that target shared oncogenic driver mutations across cancer types. It leverages pan‑cancer genomic mining, structure‑based drug design, and preclinical models (PDX, organoids) to validate compounds and co‑develop companion diagnostics, enabling biomarker‑driven adaptive trials for oncology clinicians and pharmaceutical partners.

Scribe Therapeutics engineers CRISPR-based therapeutics to modify genetic predispositions, specifically targeting cardiometabolic diseases. By creating safe and effective gene-editing solutions, the company aims to empower individuals to take control of their health outcomes rather than being limited by inherited conditions.

Talkiatry offers virtual mental healthcare by connecting patients with licensed psychiatrists through an online assessment and telehealth platform, ensuring that treatment is covered by insurance. The service addresses the challenge of accessing timely mental health support, providing personalized treatment plans for conditions such as anxiety, depression, and PTSD.

Twin Health provides an AI‑powered digital twin platform that continuously models each user’s metabolism using data from wearables, continuous glucose monitors, and other sensors. The system delivers daily, personalized recommendations for nutrition, sleep, activity, and stress, supported by a virtual clinical care team, to lower blood sugar, reduce weight, and eliminate medication. Outcomes are validated in clinical studies and billed to employers or health plans on an all‑at‑risk, results‑based basis.